Literature DB >> 12477056

Conditionally replicative adenoviruses for ovarian cancer therapy.

Mack N Barnes1, Candace J Coolidge, Akseli Hemminki, Ronald D Alvarez, David T Curiel.   

Abstract

The purpose of this review article is to present a logical rationale for the investigation of conditionally replicative adenoviral vectors for the treatment of ovarian carcinoma. A medline database search was performed to identify relevant articles in the English language for the years 1966 to present. The key words used included replicative adenovirus, conditionally replicative adenovirus, transcriptional targeting, replication selective adenovirus, and "ONYX." A total of 89 references were identified and reviewed. Each reference was reviewed for relevance to clinical translation of conditionally replicative adenoviral vector therapy for ovarian cancer. Data from current clinical trials would suggest that potential obstacles for effective replicative viral therapy of ovarian carcinoma include efficient tumor cell infection, restrictions of the cell surface coxsackie and adenovirus receptor, rapid clearance of vector in the ascites environment, tumor cells specificity, and limitations of current findings of clinical trials. The articles were, therefore, evaluated and included if they addressed these shortcomings. Current data would suggest that advanced generation conditionally replicative adenoviral vectors will soon be available for clinical trials in ovarian cancer. Ovarian cancer, because of expression of targetable receptors, transducible cells, and containment within the i.p. cavity, represents a solid tumor suited uniquely for investigation with advanced generation conditionally replicative adenoviral vectors.

Entities:  

Mesh:

Year:  2002        PMID: 12477056

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  4 in total

1.  Therapeutic efficacy of an oncolytic adenovirus containing RGD ligand in minor capsid protein IX and Fiber, Δ24DoubleRGD, in an ovarian cancer model.

Authors:  Lena J Gamble; Hideyo Ugai; Minghui Wang; Anton V Borovjagin; Qiana L Matthews
Journal:  J Mol Biochem       Date:  2012-02-15

2.  Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).

Authors:  Lena J Gamble; Anton V Borovjagin; Qiana L Matthews
Journal:  Exp Ther Med       Date:  2010-03       Impact factor: 2.447

3.  Hypoxia- and radiation-induced overexpression of Smac by an adenoviral vector and its effects on cell cycle and apoptosis in MDA-MB-231 human breast cancer cells.

Authors:  Wei-Wu Liu; Yang Liu; Shuo Liang; Jia-Hui Wu; Zhi-Cheng Wang; Shou-Liang Gong
Journal:  Exp Ther Med       Date:  2013-10-16       Impact factor: 2.447

4.  Silencing of IQGAP1 by shRNA inhibits the invasion of ovarian carcinoma HO-8910PM cells in vitro.

Authors:  Pei-Xin Dong; Nan Jia; Zhu-Jie Xu; Ying-Tao Liu; Da-Jin Li; You-Ji Feng
Journal:  J Exp Clin Cancer Res       Date:  2008-11-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.